NCT06950385 2026-03-17
SERENTA
Rapamycin Holdings Inc.
Phase 3 Recruiting
Clinical Trials
5 trialsNCT03806426 2024-04-25
Effect of EPA-FFA on Polypectomy in Familial Adenomatous Polyposis
S.L.A. Pharma AG
Phase 3 Active not recruiting
NCT01483144 2021-06-08
Trial of Eflornithine Plus Sulindac in Patients With Familial Adenomatous Polyposis (FAP)
Cancer Prevention Pharmaceuticals, Inc.
Phase 3 Completed
NCT00585312 2021-02-21
CHIP
Pfizer
Phase 3 Terminated
NCT01245816 2015-04-24
A Trial of Low Dose Sulindac Combined With Eflornithine in Patients With Familial Adenomatous Polyposis (FAP)
Cancer Prevention Pharmaceuticals, Inc.
Phase 3 Withdrawn